approval
saveGAZYVA (OBINUTUZUMAB) — FDA approval
community read0 votes
Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalOct 17, 2025 · 352d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalOct 17, 2025 · 352d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalJul 27, 2022 · 1530d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalJul 12, 2022 · 1545d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalFeb 14, 2022 · 1693d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalMar 27, 2020 · 2382d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalNov 16, 2017 · 3244d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalNov 16, 2017 · 3244d ago
same company · ±60 days · 6
- approvalmosunetuzumab: LUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approvalDec 19, 2025
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalDec 10, 2025
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalDec 10, 2025
- approval(atezolizumab + hyaluronidase (human recombinant)): TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approvalNov 24, 2025
- approval(atezolizumab + hyaluronidase (human recombinant)): TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approvalNov 17, 2025
- approvalatezolizumab: TECENTRIQ (ATEZOLIZUMAB) — FDA approvalNov 17, 2025
comments(0)
5-min edit window · permanent after that